Tagged with free

Pharma Vojtěch Mészáros, Executive Director of Egis Praha, speaks about his background in the industry, his drive to promote biosimilar products, and how the company maneuvers around the growing price pressures in the market.  You hold an impressive profile in the pharmaceutical industry. Please introduce your background and leadership to our…

Pharma Novo Nordisk Hungary GM Zsolt Jozsa highlights the growing prevalence of diabetes in Hungary, the gap in treatment options that the company is striving to close with Tresiba and Xultophy, and the limitations of Hungary’s regulatory framework. Zsolt, you took over the helm of Novo Nordisk Hungary in 2012, after…

Pharma Thépenier CEO Tsuyoshi Hasuo has imparted a unique vision to internationalize the Normandy-based French company encompassing a company turnaround and a maximization of growth potential. Together with Deputy CEO, Bertrand Lasserre, Hasuo’s mission is to capitalize upon Thépenier’s unique French-Japanese background and become a major player in cosmetics and make-up.…

Pharma Long renowned for dancing to a different tune, Italy’s eccentric, but more often than not, enlightened and high performance pharma, healthcare and life sciences community may at last be about to reign in a distinctive penchant for fragmentation. Amongst the myriad of globally recognized luxury brands promulgated by the Italian…

Pharma Eric Ducournau, CEO of Pierre Fabre Dermo-Cosmétique (PFDC), discusses the company’s revolutionary lines of dermatologically tested skincare products and their niche adapted internationalization strategy that is focused on providing the highest-quality skincare products for all consumer and patient needs. The Dermo-Cosmetics division of Pierre Fabre has represented about 55 percent…

Pharma Doppel has been selected as the nucleus for significant investments in the CDMO industry by PE firm Trilantic Capital Partners, according to recently hired CEO Giuseppe Cassisi, who shares the organization’s plans to invest in both greenfield facilities and M&A in the coming years. Italy’s pharmaceutical exports are growing faster than any other…

Pharma Janssen Czech Republic’s MD reviews his longstanding career within the company and highlights how founder Dr. Paul Janssen’s legacy still influences operations today. He also compares the Czech regulatory environment with those of its regional neighbors and finds that there is little ground for fair comparison. You have been with…

Pharma Sergio Liberatore discusses IMS Health Italy’s evolution after the acquisition of Cegedim’s CRM and strategic data businesses and how IMS is paving the way for pharma companies to become more patient-centric. When we last interviewed you in 2009, you were busy reshaping the data-provision branch, strengthening the consultancy capabilities of the business and setting…

Pharma As Egypt continues to grapple with the proliferation of the hepatitis C virus, fresh treatment, prevention and market access pathways are now being applied. Given the severity of Egypt’s hepatitis C epidemic, the national campaign against viral hepatitis remains Egypt’s top healthcare priority. According to Roche’s regional general manager, Ehab…

Pharma Concerted efforts are, at last, being made to redraw the rulebook and tidy up a local regulatory landscape long renowned for its torpor, dysfunction and ineffectuality. The Egyptian pharmaceutical market is currently regulated by the Ministry of Health itself, with all issues related to pharmaceuticals falling under the responsibility of…

Pharma Abramo Brandi, Octapharma Italy’s MD, discusses the challenges of the tender system in Italy and how he has grown the company year-on-year in the midst of a global economic crisis. What are some of your major achievements since becoming Managing Director of Octapharma Italy in 2008? I was asked to…

Pharma Mario Marazziti, President of the Italian XII Social Affairs Commission, discusses new legislation relating to clinical risk, the effects of the 2014 Pact for Health, and the efficiency of Italian healthcare in general. You were recently highly instrumental in the passing of new legislation relating to clinical risk. Could you…